| Preview
Full Doc
 | 2002 |
Dusa Pharmaceuticals Reports Corporate Update, Including a Q4 End-User Sales Increase, and 2002 Investment Spending/Financial Guidance
Dusa Pharmaceuticals Reports Corporate Update, Including a Q4 End-User Sales Increase, and 2002 Investment Spending/Financial Guidance (12K)
Doc #303087: Click preview link for longer preview.
{DOCUMENT}
{TYPE}EX-99
{SEQUENCE}3
{FILENAME}y56827ex99.txt
{DESCRIPTION}PRESS RELEASE
{TEXT}
{PAGE}
DUSA
INNOVATION IN PHOTODYNAMIC THERAPY
DUSA PHARMACEUTICALS, INC.
FOR IMMEDIATE RELEASE
DUSA PHARMACEUTICALS REPORTS CORPORATE UPDATE,
INCLUDING A Q4 END-USER SALES INCREASE, AND
2002 INVESTMENT SPENDING/FINANCIAL GUIDANCE
WILMINGTON, MASSACHUSETTS, JANUARY 21, 2002 -- - DUSA Pharmaceuticals, Inc.
(NASDAQ NMS: DUSA) reported today a corporate update, including a Q4 end-user
Kerastick(R) sales increase, the initiation of the new national reimbursement
codes for Levulan(R) Photodynamic Therapy (PDT), 2002 investment
spending/financial guidance, pipeline progress and other corporate highlights.
INCREASE IN Q4 END-USER SALES:
During the fourth quarter of 2001, DUSA continued to support Berlex
Laboratories, Inc., (a U.S. affiliate of Schering AG, Germany (FSE: SCH, NYSE:
SHR), DUSA's worldwide dermatology marketing partner (except Canada)), in its
U.S. marketing efforts of DUSA's Levulan(R) PDT for non-hyperkeratotic actinic
keratoses (AKs) of the face or scalp.
Berlex recently reported that during Q4 2001, end-user sales of Levulan(R)
Kerastick(R) brand applicators from distributors to doctors totaled 2,448 units,
a 49% increase compared to the 1,638 units sold during the prior quarter. The
increase was primarily due to increased usage at selected centers, as these
centers make Levulan(R) PDT a key part of their AK treatment regimen, based on
its benefits for patients. Although the absolute numbers are still small, and
are not a direct reflection of DUSA's Kerastick(R) revenues (which are based on
shipments from DUSA to Berlex, and from Berlex to the distributors), the
percentage increase is encouraging.
By the end of Q4, contracts for approximately 300 BLU-U(R) brand lights were in
place, net of approximately 45 returns, compared to 231 contracts at the end of
Q3, and 100 at the end of 2000. The 2001 returns were primarily related to
reimbursement concerns, which we are hopeful will diminish during 2002.
NEW NATIONAL REIMBURSEMENT CODES IN EFFECT AS OF JANUARY 1, 2002:
As previously announced, as of January 1, 2002, CPT code 96567, the new national
reimbursement code for the light application portion of Levulan(R) PDT, came
into effect, along with a "J-code" that reimburses doctors for the full cost of
the drug. Doctors may also bill for any applicable visit fees.
As the various state formularies and insurers implement these Medicare codes
over the next 3-6 months, any remaining uncertainties related to reimbursement
should be eliminated. The codes will also facilitate electronic billing for the
therapy, eliminating paperwork involved with the previous manual billing method.
DUSA is hopeful that these changes, along with Berlex's ongoing education and
marketing programs, will help build increasing acceptance of our therapy during
2002
{PAGE}
and 2003, as an important new treatment modality for this common pre-cancerous
condition.
2001/2002 INVESTMENT SPENDING/FINANCIAL GUIDANCE
As previously reported, for 2001 DUSA expects to report total revenue of
approximately $9.2 MM, including product revenues, reimbursement of 2/3rds of
agreed-upon dermatology R&D expenses by Schering AG, amortization of Schering
AG's milestone payments, and interest income. Expenses will total approximately
$16.5 MM, for a net 2001 loss of approximately $7.3 MM, or approximately $0.3 MM
above previous expectations. This was due almost entirely to increased spending
on the Barrett's esophagus dysplasia studies, as patient accrual proceeded more
quickly than originally anticipated.
For 2002, DUSA is not anticipating a significant change in revenues. The company
does expect ongoing increases in US Kerastick(R) end-user sales, especially
after the first 3-6 months, as insurance carriers adopt the new national
reimbursement codes, doctors become more comfortable with the therapy, and more
light units are placed in offices. However, because of the large Kerastick(R)
inventories still in stock at Berlex, DUSA does not expect to deliver
significant new Kerastick(R) supplies to Berlex until later in 2002, or even
into 2003, depending on sales levels. Outside of North America, Schering AG
still expects the first approvals of Levulan(R) PDT during 2002, but significant
international sales are not expected before 2003. Therefore, the Company expects
overall baseline revenues for 2002 to be similar to last year's, or
approximately $9.2 MM.
For 2002, DUSA also expects baseline expenses to be similar to 2001 levels, or
approximately $16.5 MM. This will cover its dermatology Levulan(R) PDT
development program in partnership with Schering AG, its internal Levulan(R) PDT
development program (internal costs), G&A, and other ongoing expenses (including
manufacturing and QA costs). During 2002, the Company also plans approximately
$5-6MM of additional spending, including significant expenses related to its
Barrett's esophagus dysplasia trials, its FDA-required Phase IV long-term AK
tracking study, and additional overhead related to the construction and
operation of our new Kerastick(R) manufacturing line at our Wilmington facility,
as described below.
In total, current planned expenditures for 2002 are expected to be approximately
$21.5-22.5 MM, which would result in a net loss for the year of approximately
$12.3-13.3 MM. This does not include any additional new spending that may be
required during the year, such as costs related to the potential acquisition or
development of new products or companies; any decision, in cooperation with
Schering AG, to increase Levulan(R) PDT dermatology spending levels; any
additional Levulan(R) PDT internal clinical trial costs that become justified
later in the year; and any extraordinary miscellaneous costs and expenses.
RESEARCH PIPELINE/BUSINESS DEVELOPMENT
During Q4, aggressive recruitment in our Phase I/II Levulan(R) PDT dermatology
trials for warts and onychomycosis (being conducted in cooperation with Schering
AG) led to completion of patient enrollments by year-end. Initial results are
expected from both trials during the first half of 2002, with Phase II trials to
follow, subject to satisfactory results from the current trials. The drug
dose-ranging study on acne was also completed during Q4, but the specific
low-dose protocol tested was not able to replicate the clinical efficacy seen in
previous independent research using higher doses (but which was
{PAGE}
associated with significant side effects). Further development activity to
better optimize the therapy is under consideration. However, DUSA and Schering
AG still have 3 dermatology indications under active development, including a
new AK-related indication.
As mentioned above, DUSA has decided to make a significant investment in
developing Levulan(R) PDT for the treatment of Barrett's esophagus dysplasia, a
common and serious pre-cancerous condition with no approved medical treatment.
DUSA expects preliminary results from its current trials in early-stage and
late-stage dysplasia during the first half of this year, after which it intends
to seek a development and marketing partner for this important indication.
For prevention of restenosis, we have been supporting a UK investigator study
using Levulan(R) PDT in high-risk patients with peripheral vascular disease.
However, in light of the significant recent progress made in treating this
condition with drug-coated stents, we have decided not to carry out any
additional studies at this time.
With respect to Levulan(R) PDT and PD for other internal indications, including
brain and/or bladder cancer, we continue to explore strategic alternatives to
advance development of these products.
303087
|
 BNY
As referenced in this Dusa Pharmaceuticals Reports Corporate Update, Including a Q4 End-User Sales Increase, and 2002 Investment Spending/Financial Guidance:
Bank of
New York, – the
same meeting. Mr. Bartash, an experienced healthcare and pharmaceutical analyst,
has held positions in that capacity with Aetna Life and Casualty, The Bank of
New York, Citibank and Dean Witter Reynolds. He currently provides consulting
services to the health care industry, as well as proprietary research for the
_____________
dt 282714
;
DUSA Pharma
As referenced in this Dusa Pharmaceuticals Reports Corporate Update, Including a Q4 End-User Sales Increase, and 2002 Investment Spending/Financial Guidance:
DUSA PHARMACEUTICALS, – {DOCUMENT}
{TYPE}EX-99
{SEQUENCE}3
{FILENAME}y56827ex99.txt
{DESCRIPTION}PRESS RELEASE
{TEXT}
{PAGE}
DUSA
INNOVATION IN PHOTODYNAMIC THERAPY
DUSA PHARMACEUTICALS, INC.
FOR IMMEDIATE RELEASE
DUSA PHARMACEUTICALS REPORTS CORPORATE UPDATE,
INCLUDING A Q4 END-USER SALES INCREASE, AND
2002 INVESTMENT SPENDING/FINANCIAL GUIDANCE
_____________
DUSA PHARMACEUTICALS – EX-99
{SEQUENCE}3
{FILENAME}y56827ex99.txt
{DESCRIPTION}PRESS RELEASE
{TEXT}
{PAGE}
DUSA
INNOVATION IN PHOTODYNAMIC THERAPY
DUSA PHARMACEUTICALS, INC.
FOR IMMEDIATE RELEASE
DUSA PHARMACEUTICALS REPORTS CORPORATE UPDATE,
INCLUDING A Q4 END-USER SALES INCREASE, AND
2002 INVESTMENT SPENDING/FINANCIAL GUIDANCE
WILMINGTON, MASSACHUSETTS, JANUARY 21, 2002 -- - DUSA Pharmaceuticals,
_____________
DUSA Pharmaceuticals, – DUSA PHARMACEUTICALS REPORTS CORPORATE UPDATE,
INCLUDING A Q4 END-USER SALES INCREASE, AND
2002 INVESTMENT SPENDING/FINANCIAL GUIDANCE
WILMINGTON, MASSACHUSETTS, JANUARY 21, 2002 -- - DUSA Pharmaceuticals, Inc.
(NASDAQ NMS: DUSA) reported today a corporate update, including a Q4 end-user
Kerastick(R) sales increase, the initiation of the
_____________
DUSA Pharmaceuticals, – we move
forward to increase sales of our first products, develop our pipeline, and
examine complementary technologies and products for potential acquisition".
{PAGE}
DUSA Pharmaceuticals, Inc. is a biopharmaceutical company engaged primarily in
the development of Levulan Photodynamic Therapy (PDT) and Photodetection (PD)
for multiple medical conditions.
_____________
dt 274273
;
|
Schering
As referenced in this Dusa Pharmaceuticals Reports Corporate Update, Including a Q4 End-User Sales Increase, and 2002 Investment Spending/Financial Guidance:
Schering AG, – IN Q4 END-USER SALES:
During the fourth quarter of 2001, DUSA continued to support Berlex
Laboratories, Inc., (a U.S. affiliate of Schering AG, Germany (FSE: SCH, NYSE:
SHR), DUSA's worldwide dermatology marketing partner (except Canada)), in its
U.S. marketing efforts of DUSA's
_____________
Schering AG, – report total revenue of
approximately $9.2 MM, including product revenues, reimbursement of 2/3rds of
agreed-upon dermatology R&D expenses by Schering AG, amortization of Schering
AG's milestone payments, and interest income. Expenses will total approximately
$16.5 MM, for a net 2001 loss
_____________
Schering
AG' – approximately $9.2 MM, including product revenues, reimbursement of 2/3rds of
agreed-upon dermatology R&D expenses by Schering AG, amortization of Schering
AG' s milestone payments, and interest income. Expenses will total approximately
$16.5 MM, for a net 2001 loss of approximately $7.3 MM,
_____________
Schering AG
– significant new Kerastick(R) supplies to Berlex until later in 2002, or even
into 2003, depending on sales levels. Outside of North America, Schering AG
still expects the first approvals of Levulan(R) PDT during 2002, but significant
international sales are not expected before 2003. Therefore, the
_____________
Schering AG, – be similar to 2001 levels, or
approximately $16.5 MM. This will cover its dermatology Levulan(R) PDT
development program in partnership with Schering AG, its internal Levulan(R) PDT
development program (internal costs), G&A, and other ongoing expenses (including
manufacturing and QA costs). During 2002,
_____________
dt 270048
|
| Preview
Full Doc
| 2003 |
Malan Realty Investors Announces the Sale of Two Shopping Centers; Partial Redemption Call for $7.5 Million of 9.5% Convertible Subordinated Debentures
Malan Realty Investors Announces the Sale of Two Shopping Centers; Partial Redemption Call for $7.5 Million of 9.5% Convertible Subordinated Debentures (6K)
Doc #266864: Click preview link for longer preview.
{DOCUMENT}
{TYPE}EX-99.1
{SEQUENCE}3
{FILENAME}k81635exv99w1.txt
{DESCRIPTION}PRESS RELEASE, ISSUED DECEMBER 11, 2003
{TEXT}
{PAGE}
EXHIBIT 99.1
News Release
FOR FURTHER INFORMATION:
John Roberson Fred Nachman
Media Relations Marjan Communications Inc.
(248) 644-7110 (312) 867-1771
FOR IMMEDIATE RELEASE
MALAN REALTY INVESTORS ANNOUNCES THE SALE OF
TWO SHOPPING CENTERS;
PARTIAL REDEMPTION CALL FOR
$7.5 MILLION OF 9.5% CONVERTIBLE SUBORDINATED DEBENTURES
BINGHAM FARMS, MICH., DECEMBER 11, 2003 - MALAN REALTY INVESTORS, INC.
(NYSE: MAL), a self-administered real estate investment trust (REIT),
today announced that it has completed the sale of two shopping centers
totaling 207,534 feet of gross leasable area.
The properties are the Westland Mall in Westland, Michigan, an 85,000
square-foot shopping center anchored by Dick's Sporting Goods, and
Westland Plaza in Madison, Wisconsin, a 122,534 square-foot shopping
center anchored by Burlington Coat Factory. Terms of the sale included
assumption by the purchaser of Westland Mall of the existing mortgage
with Wells Fargo Bank of $5.5 million. Net cash proceeds to Malan from
the two transactions were approximately $4.3 million.
Malan also announced it is calling for redemption on January 20, 2004,
$7.5 million of its 9.5% Convertible Subordinated Debentures due July
15, 2004. The portion of the Debentures being called will be redeemed
at par, plus accrued but unpaid interest, and retired. The aggregate
principal balance of the Debentures is currently $32.6 million, which
will decline to $19.6 million after a previously announced partial
redemption is completed December 18, 2003. "We are pleased to be
closing the year with strong property-sales activity, including these
multi-tenant shopping centers," said Jeffrey Lewis, president and chief
executive officer of Malan Realty Investors. "Upon completion of this
redemption, total debt will have decreased by more than $40 million
since the close of the third quarter, and the debentures have been
reduced by over 70 percent."
The portion of the Debentures to be redeemed will be selected by lot.
The transfer books for the Debentures will be closed on December 19,
2003 for
{PAGE}
purposes of this selection process. The transfer books will be reopened
on the next business day. The Debentures currently trade on the New
York Stock Exchange under the CUSIP number 561063-AA-6001.
Prior to 5:00 p.m., EST, on January 20, 2004, holders of Debentures
called for redemption may convert their Debentures into shares of Malan
common stock at a price of $17.00 per share, or approximately 58.82
shares per $1,000 principal amount of Debentures. Cash will be paid in
lieu of fractional shares. On December 10, 2003, the closing price of
Malan common stock on the New York Stock Exchange was $5.16 per share.
Holders of Debentures called for redemption who do not convert their
Debentures into Malan common stock will have such Debentures redeemed
on January 20, 2004. Upon redemption, they will receive $1,001.30 per
$1,000 principal amount of Notes (consisting of the redemption price of
$1,000 plus accrued and unpaid interest thereon from January 15, 2003
up to but not including January 20, 2004 of $1.30). No further interest
will accrue thereafter on Debentures called for redemption.
A notice of redemption is being mailed to all registered holders of the
Debentures, including, where applicable, information concerning the
specific Debentures selected by lot for redemption. Copies of the
notice of redemption may be obtained from The Bank of New York, the
paying agent and conversion agent, by calling Roxane Ellwanger at (312)
827-8574. The address of The Bank of New York is 2 N. LaSalle Street,
Suite 1020, Chicago, Illinois 60602.
Malan Realty Investors, Inc. owns and manages properties that are
leased primarily to national and regional retail companies. In August
2002, the company's shareholders approved a plan of complete
liquidation. The company owns a portfolio of 27 properties located in
eight states that contains an aggregate of approximately 2.2 million
square feet of gross leasable area.
Safe Harbor Statement: This news release may contain forward-looking
statements. Although the company believes that the statements and
projections are based on reasonable assumptions, actual results may
differ from those projected. Key factors that could cause actual
results to differ materially include uncertainties regarding the length
of time required to sell the company's properties and execute the plan
of liquidation, expenses incurred during the liquidation period, the
company's ability to retire or refinance its indebtedness as it comes
due, its success in selling assets, the changing market conditions
affecting the sale prices of its properties, the disproportionate
effect of changes in proceeds from property sales on liquidating
distributions due to the company's capital structure, economic
downturns, leasing activities, the outcome of the company's appeal of
the court's decision affirming the Gramer litigation, bankruptcies and
other financial difficulties of tenants, the cost of addressing
environmental concerns, unforeseen contingent liabilities, other risks
associated with the commercial real-estate
{PAGE}
business, and other concerns as detailed in the company's filings from
time to time with the Securities and Exchange Commission.
News releases for Malan Realty Investors are available on the company's
Web site at www.malanreit.com or in the Company News section on the PR
Newswire Web site at www.prnewswire.com.
# # #
{/TEXT}
{/DOCUMENT}
266864
|
BNY
As referenced in this Malan Realty Investors Announces the Sale of Two Shopping Centers; Partial Redemption Call for $7.5 Million of 9.5% Convertible Subordinated Debentures:
Bank of New York, – where applicable, information concerning the
specific Debentures selected by lot for redemption. Copies of the
notice of redemption may be obtained from The Bank of New York, the
paying agent and conversion agent, by calling Roxane Ellwanger at (312)
827-8574. The address of The Bank of New York
_____________
Bank of New York – The Bank of New York, the
paying agent and conversion agent, by calling Roxane Ellwanger at (312)
827-8574. The address of The Bank of New York is 2 N. LaSalle Street,
Suite 1020, Chicago, Illinois 60602.
Malan Realty Investors, Inc. owns and manages properties that are
leased primarily to
_____________
dt 168918
;
|
Malan Realty
As referenced in this Malan Realty Investors Announces the Sale of Two Shopping Centers; Partial Redemption Call for $7.5 Million of 9.5% Convertible Subordinated Debentures:
MALAN REALTY INVESTORS – News Release
FOR FURTHER INFORMATION:
John Roberson Fred Nachman
Media Relations Marjan Communications Inc.
(248) 644-7110 (312) 867-1771
FOR IMMEDIATE RELEASE
MALAN REALTY INVESTORS ANNOUNCES THE SALE OF
TWO SHOPPING CENTERS;
PARTIAL REDEMPTION CALL FOR
$7.5 MILLION OF 9.5% CONVERTIBLE SUBORDINATED DEBENTURES
BINGHAM FARMS, MICH.,
_____________
MALAN REALTY INVESTORS, – OF
TWO SHOPPING CENTERS;
PARTIAL REDEMPTION CALL FOR
$7.5 MILLION OF 9.5% CONVERTIBLE SUBORDINATED DEBENTURES
BINGHAM FARMS, MICH., DECEMBER 11, 2003 - MALAN REALTY INVESTORS, INC.
(NYSE: MAL), a self-administered real estate investment trust (REIT),
today announced that it has completed the sale of two shopping
_____________
Malan Realty Investors. – closing the year with strong property-sales activity, including these
multi-tenant shopping centers," said Jeffrey Lewis, president and chief
executive officer of Malan Realty Investors. "Upon completion of this
redemption, total debt will have decreased by more than $40 million
since the close of the third quarter,
_____________
Malan Realty Investors, – Ellwanger at (312)
827-8574. The address of The Bank of New York is 2 N. LaSalle Street,
Suite 1020, Chicago, Illinois 60602.
Malan Realty Investors, Inc. owns and manages properties that are
leased primarily to national and regional retail companies. In August
2002, the company's shareholders
_____________
Malan Realty Investors – and other concerns as detailed in the company's filings from
time to time with the Securities and Exchange Commission.
News releases for Malan Realty Investors are available on the company's
Web site at www.malanreit.com or in the Company News section on the PR
Newswire Web
_____________
dt 174999
|
| Preview
Full Doc
| 2003 |
Malan Realty Investors Announces Sale of Four Properties to Kmart Corporation; Partial Redemption Call for $13.0 Million of 9.5% Convertible Subordinated Debentures
Malan Realty Investors Announces Sale of Four Properties to Kmart Corporation; Partial Redemption Call for $13.0 Million of 9.5% Convertible Subordinated Debentures (6K)
Doc #266868: Click preview link for longer preview.
{DOCUMENT}
{TYPE}EX-99.1
{SEQUENCE}3
{FILENAME}k80610exv99w1.txt
{DESCRIPTION}PRESS RELEASE DATED NOVEMBER 7, 2003
{TEXT}
{PAGE}
EXHIBIT 99.1
News Release
FOR FURTHER INFORMATION:
John Roberson Fred Nachman
Media Relations Marjan Communications Inc.
(248) 644-7110 (312) 867-1771
FOR IMMEDIATE RELEASE
MALAN REALTY INVESTORS ANNOUNCES SALE OF
FOUR PROPERTIES TO KMART CORPORATION;
PARTIAL REDEMPTION CALL FOR
$13.0 MILLION OF 9.5% CONVERTIBLE SUBORDINATED DEBENTURES
BINGHAM FARMS, MICH., NOVEMBER 7, 2003 - MALAN REALTY INVESTORS, INC.
(NYSE: MAL), a self-administered real estate investment trust (REIT),
today announced it has completed the sale of four Kmart properties to
Kmart Corporation.
The properties, which total 400,870 square feet of gross leasable area,
are located at 7050 S. Pulaski Avenue in Chicago, 17355 Torrence Avenue
in the Chicago suburb of Lansing, and in Fort Atkinson and Kenosha,
Wisconsin. The properties consist of four Kmart stores and in-line
stores at the Wisconsin properties. The properties sold for $10.92
million, after expenses.
Malan also announced it is calling for redemption on December 18, 2003,
$13.0 million of its 9.5% Convertible Subordinated Debentures due July
15, 2004. The portion of the Debentures being called will be redeemed
at par, plus accrued but unpaid interest, and retired. The aggregate
principal balance of the Debentures is currently $32.5 million.
"Malan has made excellent progress during recent months in selling
properties and reducing debt," said Jeffrey Lewis, president and chief
executive officer of Malan Realty Investors. "We have paid off loan
obligations and have reduced the balance on Debentures by more than
half so far this year."
The portion of the Debentures to be redeemed will be selected by lot.
The transfer books for the Debentures will be closed on November 17,
2003 for purposes of this selection process. The transfer books will be
reopened on the
{PAGE}
next business day. The Debentures currently trade on the New York Stock
Exchange under the CUSIP number 561063-AA-6001.
Prior to 5:00 p.m., Eastern time, on December 18, 2003, holders of
Debentures called for redemption may convert their Debentures into
shares of Malan common stock at a price of $17.00 per share, or
approximately 58.82 shares per $1,000 principal amount of Debentures.
Cash will be paid in lieu of fractional shares. On November 6, 2003,
the closing price of Malan common stock on the New York Stock Exchange
was $4.78 per share.
Holders of Debentures called for redemption who do not convert their
Debentures into Malan common stock will have such Debentures redeemed
on December 18, 2003. Upon redemption, they will receive $1,039.78 per
$1,000 principal amount of Notes (consisting of the redemption price of
$1,000 plus accrued and unpaid interest thereon from July 15, 2003 up
to but not including December 18, 2003 of $39.78). No further interest
will accrue thereafter on Debentures called for redemption.
A notice of redemption is being mailed to all registered holders of the
Debentures, including, where applicable, information concerning the
specific Debentures selected by lot for redemption. Copies of the
notice of redemption may be obtained from The Bank of New York, the
paying agent and conversion agent, by calling Roxane Ellwanger at (312)
827-8574. The address of The Bank of New York is 2 N. LaSalle Street,
Suite 1020, Chicago, Illinois 60602.
Malan Realty Investors, Inc. owns and manages properties that are
leased primarily to national and regional retail companies. In August
2002, the company's shareholders approved a plan of complete
liquidation. The company owns a portfolio of 30 properties located in
eight states that contains an aggregate of approximately 2.46 million
square feet of gross leasable area.
Safe Harbor Statement: This news release may contain forward-looking
statements. Although the company believes that the statements and
projections are based on reasonable assumptions, actual results may
differ from those projected. Key factors that could cause actual
results to differ materially include uncertainties regarding the length
of time required to sell the company's properties and execute its plan
of liquidation and expenses incurred during the liquidation period,
changing market conditions affecting the sales price of the company's
properties, the disproportionate effect of changes in proceeds from
property sales on liquidating distributions due to the company's
capital structure, the cost of litigation in which the company is
involved, bankruptcies and other financial difficulties of tenants, the
cost of addressing environmental concerns, unforeseen contingent
liabilities, and other risks associated with the commercial real estate
business, as detailed in the company's filings from time to time with
the Securities and Exchange Commission. Many of these factors are
beyond the control of the company. Malan does not undertake to update
these forward-looking statements.
News releases for Malan Realty Investors are available on the company's
Web site at www.malanreit.com or on the PR Newswire Web site at
www.prnewswire.com.
# # #
{/TEXT}
{/DOCUMENT}
266868
|
BNY
As referenced in this Malan Realty Investors Announces Sale of Four Properties to Kmart Corporation; Partial Redemption Call for $13.0 Million of 9.5% Convertible Subordinated Debentures:
Bank of New York, – where applicable, information concerning the
specific Debentures selected by lot for redemption. Copies of the
notice of redemption may be obtained from The Bank of New York, the
paying agent and conversion agent, by calling Roxane Ellwanger at (312)
827-8574. The address of The Bank of New York
_____________
Bank of New York – The Bank of New York, the
paying agent and conversion agent, by calling Roxane Ellwanger at (312)
827-8574. The address of The Bank of New York is 2 N. LaSalle Street,
Suite 1020, Chicago, Illinois 60602.
Malan Realty Investors, Inc. owns and manages properties that are
leased primarily to
_____________
dt 168919
;
|
Malan Realty
As referenced in this Malan Realty Investors Announces Sale of Four Properties to Kmart Corporation; Partial Redemption Call for $13.0 Million of 9.5% Convertible Subordinated Debentures:
MALAN REALTY INVESTORS – News Release
FOR FURTHER INFORMATION:
John Roberson Fred Nachman
Media Relations Marjan Communications Inc.
(248) 644-7110 (312) 867-1771
FOR IMMEDIATE RELEASE
MALAN REALTY INVESTORS ANNOUNCES SALE OF
FOUR PROPERTIES TO KMART CORPORATION;
PARTIAL REDEMPTION CALL FOR
$13.0 MILLION OF 9.5% CONVERTIBLE SUBORDINATED DEBENTURES
BINGHAM FARMS,
_____________
MALAN REALTY INVESTORS, – PROPERTIES TO KMART CORPORATION;
PARTIAL REDEMPTION CALL FOR
$13.0 MILLION OF 9.5% CONVERTIBLE SUBORDINATED DEBENTURES
BINGHAM FARMS, MICH., NOVEMBER 7, 2003 - MALAN REALTY INVESTORS, INC.
(NYSE: MAL), a self-administered real estate investment trust (REIT),
today announced it has completed the sale of four Kmart properties
_____________
Malan Realty Investors. – Malan has made excellent progress during recent months in selling
properties and reducing debt," said Jeffrey Lewis, president and chief
executive officer of Malan Realty Investors. "We have paid off loan
obligations and have reduced the balance on Debentures by more than
half so far this year."
The
_____________
Malan Realty Investors, – Ellwanger at (312)
827-8574. The address of The Bank of New York is 2 N. LaSalle Street,
Suite 1020, Chicago, Illinois 60602.
Malan Realty Investors, Inc. owns and manages properties that are
leased primarily to national and regional retail companies. In August
2002, the company's shareholders
_____________
Malan Realty Investors – of these factors are
beyond the control of the company. Malan does not undertake to update
these forward-looking statements.
News releases for Malan Realty Investors are available on the company's
Web site at www.malanreit.com or on the PR Newswire Web site at
www.prnewswire.com.
# # #
{/
_____________
dt 175003
|
| Preview
Full Doc
| 2003 |
Malan Realty Investors Announces Partial Redemption Call for $10 Million of 9.5% Convertible Subordinated Debentures
Malan Realty Investors Announces Partial Redemption Call for $10 Million of 9.5% Convertible Subordinated Debentures (4K)
Doc #266869: Click preview link for longer preview.
{DOCUMENT}
{TYPE}EX-99.1
{SEQUENCE}3
{FILENAME}k79850exv99w1.txt
{DESCRIPTION}PRESS RELEASE
{TEXT}
{PAGE}
EXHIBIT 99.1
News Release
FOR FURTHER INFORMATION:
John Roberson Fred Nachman
Media Relations Marjan Communications Inc.
(248) 644-7110 (312) 867-1771
FOR IMMEDIATE RELEASE
MALAN REALTY INVESTORS ANNOUNCES
PARTIAL REDEMPTION CALL FOR
$10 MILLION OF 9.5% CONVERTIBLE SUBORDINATED DEBENTURES
BINGHAM FARMS, MICH., SEPTEMBER 25, 2003 - MALAN REALTY INVESTORS, INC.
(NYSE: MAL), a self-administered real estate investment trust (REIT),
today announced it is calling for redemption on October 27, 2003 $10
million of its 9.5% Convertible Subordinated Debentures due July 15,
2004. The portion of the Debentures being called will be redeemed at
par, plus accrued but unpaid interest, and retired. The aggregate
principal balance of the Debentures is currently $42.7 million.
The portion of the Debentures to be redeemed will be selected by lot.
The transfer books for the Debentures will be closed on September 26,
2003 for purposes of this selection process. The transfer books will be
reopened on September 29, 2003. The Debentures currently trade on the
New York Stock Exchange under the symbol MAL04. The CUSIP number of the
Debentures is 561063AA6001.
Prior to 5:00 p.m. EDT on October 27, 2003, holders of Debentures
called for redemption may convert their Debentures into shares of Malan
common stock at a price of $17.00 per share, or approximately 58.82
shares per $1,000 principal amount of Debentures. Cash will be paid in
lieu of fractional shares. On September 24, 2003, the
{PAGE}
closing price of Malan common stock on the New York Stock Exchange was
$4.61 per share.
Holders of Debentures called for redemption who do not convert their
Debentures into Malan common stock will have such Debentures redeemed
on October 27, 2003. Upon redemption, they will receive $1,026.92 per
$1,000 principal amount of Notes (consisting of the redemption price of
$1,000 plus accrued and unpaid interest thereon from July 15, 2003 up
to but not including October 27, 2003 of $26.92). No further interest
will accrue thereafter on Debentures called for redemption.
A notice of redemption is being mailed to all registered holders of the
Debentures, including, where applicable, information concerning the
specific Debentures selected by lot for redemption. Copies of the
notice of redemption may be obtained from The Bank of New York, the
paying agent and conversion agent, by calling Roxane Ellwanger at (312)
827-8574. The address of The Bank of New York is 2 N. LaSalle Street,
Suite 1020, Chicago, IL 60602.
Malan Realty Investors, Inc. owns and manages properties that are
leased primarily to national and regional retail companies. In August
2002, the company's shareholders approved a plan of complete
liquidation. The company owns a portfolio of 34 properties located in
eight states that contains an aggregate of approximately 2.9 million
square feet of gross leasable area.
News releases for Malan Realty Investors are available on the company's
Web site at www.malanreit.com or through Company News On-Call by fax at
(800) 758-5804, ext. 114165, or www.prnewswire.com.
# # #
{/TEXT}
{/DOCUMENT}
266869
|
BNY
As referenced in this Malan Realty Investors Announces Partial Redemption Call for $10 Million of 9.5% Convertible Subordinated Debentures:
Bank of New York, – where applicable, information concerning the
specific Debentures selected by lot for redemption. Copies of the
notice of redemption may be obtained from The Bank of New York, the
paying agent and conversion agent, by calling Roxane Ellwanger at (312)
827-8574. The address of The Bank of New York
_____________
Bank of New York – The Bank of New York, the
paying agent and conversion agent, by calling Roxane Ellwanger at (312)
827-8574. The address of The Bank of New York is 2 N. LaSalle Street,
Suite 1020, Chicago, IL 60602.
Malan Realty Investors, Inc. owns and manages properties that are
leased primarily to
_____________
dt 168920
;
|
Malan Realty
As referenced in this Malan Realty Investors Announces Partial Redemption Call for $10 Million of 9.5% Convertible Subordinated Debentures:
MALAN REALTY INVESTORS – News Release
FOR FURTHER INFORMATION:
John Roberson Fred Nachman
Media Relations Marjan Communications Inc.
(248) 644-7110 (312) 867-1771
FOR IMMEDIATE RELEASE
MALAN REALTY INVESTORS ANNOUNCES
PARTIAL REDEMPTION CALL FOR
$10 MILLION OF 9.5% CONVERTIBLE SUBORDINATED DEBENTURES
BINGHAM FARMS, MICH., SEPTEMBER 25, 2003 - MALAN REALTY INVESTORS, INC.
(
_____________
MALAN REALTY INVESTORS, – RELEASE
MALAN REALTY INVESTORS ANNOUNCES
PARTIAL REDEMPTION CALL FOR
$10 MILLION OF 9.5% CONVERTIBLE SUBORDINATED DEBENTURES
BINGHAM FARMS, MICH., SEPTEMBER 25, 2003 - MALAN REALTY INVESTORS, INC.
(NYSE: MAL), a self-administered real estate investment trust (REIT),
today announced it is calling for redemption on October 27, 2003 $
_____________
Malan Realty Investors, – Ellwanger at (312)
827-8574. The address of The Bank of New York is 2 N. LaSalle Street,
Suite 1020, Chicago, IL 60602.
Malan Realty Investors, Inc. owns and manages properties that are
leased primarily to national and regional retail companies. In August
2002, the company's shareholders
_____________
Malan Realty Investors – properties located in
eight states that contains an aggregate of approximately 2.9 million
square feet of gross leasable area.
News releases for Malan Realty Investors are available on the company's
Web site at www.malanreit.com or through Company News On-Call by fax at
(800) 758-
_____________
dt 175004
|
| Full Doc
| 2003 |
Asiacontent.com Announces Distribution to Shareholders
Asiacontent.com Announces Distribution to Shareholders (2K)
Doc #275866: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-1
{SEQUENCE}3
{FILENAME}d54414_ex1.txt
{DESCRIPTION}PRESS RELEASE
{TEXT}
Exhibit 1
Asiacontent.com Announces Distribution to Shareholders
Hong Kong/New York, March 17, 2003 - Asiacontent.com, Ltd. (OTC BB: IASIF.OB)
(the "Company") today announced that it had distributed a report to the
Company's shareholders concerning the progress of the Company's voluntary
liquidation and that it will make an initial distribution to shareholders.
The Company will make an initial distribution of $1.46 per share to shareholders
of record as of July 10, 2002, the date that the Company share register was
closed upon the filing of the Plan of Dissolution. This amount represents
approximately 85 percent of the currently estimated net assets of the Company
available for distribution.
The distribution will be effected by the Bank of New York, the company's
distribution agent, and is expected to take place on or about April 4, 2003.
An estimated final distribution of $0.26 per share to members will be made upon
completion of the liquidation, which the Company expects to occur by July 2004.
However, this estimate is subject to change. Events which could cause the
Company to change its estimate include amounts realized by collection of
book debts, the progress of the liquidation, any litigation in which the Company
is involved and unknown liabilities.
As previously announced, the Company commenced voluntary winding up and
liquidation on July 10, 2002.
--------------------------------------------------------------------------------
This release contains forward-looking statements with respect to the Company's
liquidation and dissolution. Factors that may cause actual results to differ
materially from these forward-looking statements include the following: amounts
to be realized in connection with the sale of the Company's assets, the ability
of the Company to effect an orderly wind down of its operations, the possible
delay in implementation or termination of the Company's plans of liquidation and
dissolution, the timing and amount of payments to shareholders, the effect of
litigation in which the Company is involved and unknown liabilities which may be
asserted in connection with the liquidation. Please refer to the Company's
Annual Report on Form 20-F for the fiscal year ended December 31, 2001 and the
Company's other filings with the SEC from time to time, for a description of
certain additional factors which may cause results to differ materially from
those indicated by these forward-looking statements.
6
{/TEXT}
{/DOCUMENT}
275866
|
BNY
As referenced in this Asiacontent.com Announces Distribution to Shareholders:
Bank of New York, – represents
approximately 85 percent of the currently estimated net assets of the Company
available for distribution.
The distribution will be effected by the Bank of New York, the company's
distribution agent, and is expected to take place on or about April 4, 2003.
An estimated final distribution of $
_____________
dt 185029
;
|
AsiaContent.com
As referenced in this Asiacontent.com Announces Distribution to Shareholders:
Asiacontent.com – {DOCUMENT}
{TYPE}EX-1
{SEQUENCE}3
{FILENAME}d54414_ex1.txt
{DESCRIPTION}PRESS RELEASE
{TEXT}
Exhibit 1
Asiacontent.com Announces Distribution to Shareholders
Hong Kong/New York, March 17, 2003 - Asiacontent.com, Ltd. (OTC BB: IASIF.OB)
(the "Company") today announced that
_____________
Asiacontent.com, – 3
{FILENAME}d54414_ex1.txt
{DESCRIPTION}PRESS RELEASE
{TEXT}
Exhibit 1
Asiacontent.com Announces Distribution to Shareholders
Hong Kong/New York, March 17, 2003 - Asiacontent.com, Ltd. (OTC BB: IASIF.OB)
(the "Company") today announced that it had distributed a report to the
Company's shareholders concerning the
_____________
dt 192215
|
| Preview
Full Doc
| 2003 |
Corixa Reports Second Quarter Financial Results
Corixa Reports Second Quarter Financial Results (13K)
Doc #289030: Click preview link for longer preview.
For more information:
Investor Relations
Media Relations
Cindy Moon
Colleen Beauregard
Corixa Corp.
Waggener Edstrom Bioscience
206.754.5931
503.443.7000
moon@corixa.com
colleenb@wagged.com
FOR IMMEDIATE RELEASE
CORIXA REPORTS SECOND QUARTER FINANCIAL RESULTS
Seattle, July 31, 2003 ? Corixa Corp. (Nasdaq: CRXA), a developer of immunotherapeutics, today announced financial results for the second quarter ended June 30, 2003.
For the second quarter of 2003, Corixa . . .
289030
|
BNY
As referenced in this Corixa Reports Second Quarter Financial Results:
Bank of New York. – to have access to, subject to certain conditions, a $75 million equity line of credit from BNY Capital Markets, a subsidiary of the Bank of New York. As of June 30, 2003, draws under the credit line totaled $2.6 million.
Second Quarter Developments:
The FDA approved BEXXAR for
_____________
dt 236080
;
Corixa
As referenced in this Corixa Reports Second Quarter Financial Results:
Corixa Corp – EX-99.1 3 v91907exv99w1.htm EXHIBIT 99.1
EXHIBIT 99.1
For more information:
Investor Relations
Media Relations
Cindy Moon
Colleen Beauregard
Corixa Corp .
Waggener Edstrom Bioscience
206.754.5931
503.443.7000
moon@corixa.com
colleenb@wagged.com
FOR IMMEDIATE RELEASE
CORIXA REPORTS SECOND QUARTER
_____________
Corixa Corp – 5931
503.443.7000
moon@corixa.com
colleenb@wagged.com
FOR IMMEDIATE RELEASE
CORIXA REPORTS SECOND QUARTER FINANCIAL RESULTS
Seattle, July 31, 2003 Corixa Corp . (Nasdaq: CRXA), a developer of immunotherapeutics, today announced financial results for the second quarter ended June 30, 2003.
For the second quarter
_____________
Corixa Corp – are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.
# # #
-MORE-
Corixa Corp oration
Consolidated Statement of Operations
(In thousands except per share data)
Three months ended June 30,
Six months ended June 30,
2003
2002
_____________
dt 238518
;
| |
| Preview
Full Doc
| 2003 |
Elan Announces Results of Offer to Purchase Lyons(TM) Due 2018
Elan Announces Results of Offer to Purchase Lyons(TM) Due 2018 (1K)
Doc #302585: Click preview link for longer preview.
{DOCUMENT}
{TYPE}EX-99.1
{SEQUENCE}3
{FILENAME}elan6k121703ex991.txt
{DESCRIPTION}PRESS RELEASE
{TEXT}
Exhibit 99.1
FOR IMMEDIATE RELEASE
Investors: Media:
Emer Reynolds Anita Kawatra
Ph: 353-1-709-4000 Ph: 212-407-5755
800-252-3526 800-252-3526
ELAN ANNOUNCES RESULTS OF OFFER TO PURCHASE LYONS(TM) DUE 2018
DUBLIN, IRELAND, DECEMBER 16, 2003 -- Elan Corporation, plc today announced the
results of its offer to purchase its Liquid Yield Option(TM) Notes due 2018
(Zero Coupon--Subordinated) (the "LYONs"). Pursuant to the indenture under which
the LYONs were issued, the holders' option to surrender their LYONs for
repurchase expired at 5:00 p.m. Eastern Standard Time on Monday, December 15,
2003.
Elan has been advised by the trustee for the LYONs, The Bank of New York, that
LYONs with an aggregate principal amount at maturity of approximately $799.7
million were validly surrendered for repurchase and not withdrawn, and Elan has
repurchased all of such LYONs. Approximately $1.6 million in aggregate principal
amount at maturity of LYONs remain outstanding following the completion of the
repurchase. The purchase price for the LYONs was $616.57 in cash per $1,000
principal amount at maturity of the LYONs. The aggregate purchase price for all
LYONs validly surrendered for repurchase and not withdrawn was approximately
$493.1 million.
About Elan
Elan is focused on the discovery, development, manufacturing, sale and marketing
of novel therapeutic products in neurology, severe pain and autoimmune diseases.
Elan (NYSE: ELN) shares trade on the New York, London and Dublin Stock
Exchanges.
{/TEXT}
{/DOCUMENT}
302585
|
BNY
As referenced in this Elan Announces Results of Offer to Purchase Lyons(TM) Due 2018:
Bank of New York, – 5:00 p.m. Eastern Standard Time on Monday, December 15,
2003.
Elan has been advised by the trustee for the LYONs, The Bank of New York, that
LYONs with an aggregate principal amount at maturity of approximately $799.7
million were validly surrendered for repurchase and not withdrawn,
_____________
dt 267696
;
|
Elan
As referenced in this Elan Announces Results of Offer to Purchase Lyons(TM) Due 2018:
Elan Corp – 5755
800-252-3526 800-252-3526
ELAN ANNOUNCES RESULTS OF OFFER TO PURCHASE LYONS(TM) DUE 2018
DUBLIN, IRELAND, DECEMBER 16, 2003 -- Elan Corp oration, plc today announced the
results of its offer to purchase its Liquid Yield Option(TM) Notes due 2018
(Zero Coupon--Subordinated) (the "
_____________
dt 271393
|
| Preview
Full Doc
| 2003 |
Elan Announces Results of Offer to Purchase Lyons(TM) Due 2018
Elan Announces Results of Offer to Purchase Lyons(TM) Due 2018 (1K)
Doc #302587: Click preview link for longer preview.
{DOCUMENT}
{TYPE}EX-99
{SEQUENCE}3
{FILENAME}elanscto121603ex99a5b.txt
{DESCRIPTION}PRESS RELASEL
{TEXT}
Exhibit 99(a)(5)(B)
FOR IMMEDIATE RELEASE
Investors: Media:
Emer Reynolds Anita Kawatra
Ph: 353-1-709-4000 Ph: 212-407-5755
800-252-3526 800-252-3526
ELAN Announces Results Of Offer To Purchase LYONs(TM) Due 2018
Dublin, Ireland, December 16, 2003-- Elan Corporation, plc today announced the
results of its offer to purchase its Liquid Yield Option(TM) Notes due 2018
(Zero Coupon--Subordinated) (the "LYONs"). Pursuant to the indenture under which
the LYONs were issued, the holders' option to surrender their LYONs for
repurchase expired at 5:00 p.m. Eastern Standard Time on Monday, December 15,
2003.
Elan has been advised by the trustee for the LYONs, The Bank of New York, that
LYONs with an aggregate principal amount at maturity of approximately $799.7
million were validly surrendered for repurchase and not withdrawn, and Elan has
repurchased all of such LYONs. Approximately $1.6 million in aggregate principal
amount at maturity of LYONs remain outstanding following the completion of the
repurchase. The purchase price for the LYONs was $616.57 in cash per $1,000
principal amount at maturity of the LYONs. The aggregate purchase price for all
LYONs validly surrendered for repurchase and not withdrawn was approximately
$493.1 million.
About Elan
Elan is focused on the discovery, development, manufacturing, sale and marketing
of novel therapeutic products in neurology, severe pain and autoimmune diseases.
Elan (NYSE: ELN) shares trade on the New York, London and Dublin Stock
Exchanges.
{/TEXT}
{/DOCUMENT}
302587
|
BNY
As referenced in this Elan Announces Results of Offer to Purchase Lyons(TM) Due 2018:
Bank of New York, – 5:00 p.m. Eastern Standard Time on Monday, December 15,
2003.
Elan has been advised by the trustee for the LYONs, The Bank of New York, that
LYONs with an aggregate principal amount at maturity of approximately $799.7
million were validly surrendered for repurchase and not withdrawn,
_____________
dt 267698
;
|
Elan
As referenced in this Elan Announces Results of Offer to Purchase Lyons(TM) Due 2018:
Elan Corp – 5755
800-252-3526 800-252-3526
ELAN Announces Results Of Offer To Purchase LYONs(TM) Due 2018
Dublin, Ireland, December 16, 2003-- Elan Corp oration, plc today announced the
results of its offer to purchase its Liquid Yield Option(TM) Notes due 2018
(Zero Coupon--Subordinated) (the "
_____________
dt 271394
|
| Preview
Full Doc
| 2003 |
Elan Announces Commencement of Tender Period for Lyons(TM) Due 2018
Elan Announces Commencement of Tender Period for Lyons(TM) Due 2018 (7K)
Doc #302593: Click preview link for longer preview.
{DOCUMENT}
{TYPE}EX-99.1
{SEQUENCE}3
{FILENAME}elan6k111403ex991.txt
{DESCRIPTION}PRESS RELEASE
{TEXT}
Exhibit 99.1
FOR IMMEDIATE RELEASE
Investors: Media:
Emer Reynolds Anita Kawatra
Ph: 353-1-709-4000 Ph: 212-407-5755
800-252-3526 800-252-3526
ELAN ANNOUNCES COMMENCEMENT OF TENDER PERIOD FOR LYONS(TM) DUE
2018
DUBLIN IRELAND, NOVEMBER 14, 2003-- Elan Corporation, plc (NYSE: ELN) today
announced that holders of Liquid Yield Option(TM) Notes due 2018 (Zero
Coupon--Subordinated) (the "LYONs") issued by its wholly-owned subsidiary, Elan
Finance Corporation Ltd., have the right to surrender their LYONs for purchase
during the period that begins today and ends on Monday, December 15, 2003.
Pursuant to the indenture under which the LYONs were issued in December 1998,
each holder of LYONs has the right to require Elan to purchase, until 5:00 p.m.,
New York time, on Monday, December 15, 2003, such holder's LYONs at a price
equal to $616.57 per $1,000 principal amount at maturity of the LYONs.
Under the terms of the LYONs, Elan had the option to pay for the LYONs in cash,
in American Depositary Shares ("ADSs"), representing Ordinary Shares, of Elan,
or in any combination of cash and ADSs. Elan has elected to pay for the LYONs in
cash. The aggregate principal amount due at maturity for all outstanding LYONs
is approximately $801.2 million. If all outstanding LYONs were surrendered for
purchase, the aggregate cash purchase price would be approximately $494 million.
Elan intends to use a portion of the net proceeds from its recently completed
offerings of Ordinary Shares and 6.5% Guaranteed Convertible Notes due 2008 to
repurchase the LYONs.
In order to surrender LYONs for purchase, holders must deliver a purchase notice
to The Bank of New York, the trustee and paying agent for the LYONs, on or
before 5:00 p.m., New York time, on Monday, December 15, 2003. Holders may
withdraw any LYONs previously surrendered for purchase at any time prior to 5:00
p.m., New York time, on Monday, December 15, 2003.
{PAGE}
Elan Announces Commencement of Tender Period for LYONs(TM) due 2018
Page 2
Elan filed a Tender Offer Statement on Form TO with the Securities and Exchange
Commission today. Elan will make available to LYONs holders, through The
Depository Trust Company, documents specifying the terms, conditions and
procedures for surrendering for purchase and withdrawing LYONs. LYONs holders
are encouraged to read these documents carefully before making any decision with
respect to the surrender of LYONs, because these documents contain important
information regarding the details of Elan's obligation to purchase LYONs.
The LYONs are exchangeable into 13.75 Elan ADSs per $1,000 principal amount at
maturity of LYONs, subject to certain conditions set forth in the indenture and
in the LYONs, and subject to adjustment under certain circumstances.
This press release does not constitute an offer to purchase LYONs. The offer to
purchase is made solely by Elan's notice dated November 14, 2003.
About Elan
Elan is focused on the discovery, development, manufacturing, selling and
marketing of novel therapeutic products in neurology, pain management and
autoimmune diseases. Elan shares trade on the New York, London and Irish Stock
Exchanges.
The recent offerings of Ordinary Shares and Guaranteed Convertible Notes were
made outside the United States to non-U.S. persons in reliance on Regulation S
under the Securities Act of 1933, as amended (the "Securities Act"). The
Ordinary Shares, the Guaranteed Convertible Notes, the guarantee of the
Guaranteed Convertible Notes and the shares to be issued upon conversion of the
Guaranteed Convertible Notes have not been and will not be registered under the
Securities Act and, unless so registered, may not be offered, sold or
distributed within the United States or to U.S. persons (as defined in
Regulation S under the Securities Act) except pursuant to an exemption from, or
in a transaction not subject to, the registration requirements of the Securities
Act. This release does not constitute an offer to sell or the solicitation of an
offer to buy any Guaranteed Convertible Notes or Ordinary Shares.
This document contains forward-looking statements about Elan's financial
condition, results of operations and business prospects that involve substantial
risks and uncertainties. You can identify these statements by the fact that they
use words such as "anticipate", "estimate", "project", "envisage", "intend",
"plan", "believe" and other words
{PAGE}
Elan Announces Commencement of Tender Period for LYONs(TM) due 2018
Page 3
and terms of similar meaning in connection with any discussion of future
operating or financial performance or events. Among the factors that could cause
actual results to differ materially from those described herein are the
following: the outcome of Elan's recovery plan and its ability to maintain
flexibility and maintain sufficient cash, liquid resources, and investments and
other assets capable of being monetised to meet its liquidity requirements; the
outcome of the ongoing SEC investigation and the shareholder and other pending
litigation; the success of research and development activities and the speed
with which regulatory authorisations and product launches may be achieved;
competitive developments affecting Elan's current products; the ability to
successfully market both new and existing products; difficulties or delays in
manufacturing; the ability to meet generic and branded competition after the
expiration of Elan's patents; the trend towards managed care and health care
cost containment; possible legislation affecting pharmaceutical pricing;
exposure to product liability and other types of lawsuits; Elan's ability to
protect its intellectual property; interest rate and foreign currency exchange
rate fluctuations; governmental laws and regulations affecting domestic and
foreign operations, including tax obligations; general changes in U.S. and Irish
generally accepted accounting principles; growth in costs and expenses; changes
in product mix; and the impact of acquisitions, divestitures, restructurings,
product withdrawals and other unusual items. A further list and description of
these risks, uncertainties and other matters can be found in Elan's Annual
Report on Form 20-F for the fiscal year ended December 31, 2002, and in its
Reports of Foreign Issuer on Form 6-K. Elan assumes no obligation to update any
forward-looking statements, whether as a result of new information, future
events or otherwise.
{/TEXT}
{/DOCUMENT}
302593
|
BNY
As referenced in this Elan Announces Commencement of Tender Period for Lyons(TM) Due 2018:
Bank of New York, – Convertible Notes due 2008 to
repurchase the LYONs.
In order to surrender LYONs for purchase, holders must deliver a purchase notice
to The Bank of New York, the trustee and paying agent for the LYONs, on or
before 5:00 p.m., New York time, on Monday, December 15,
_____________
dt 267700
;
|
Elan
As referenced in this Elan Announces Commencement of Tender Period for Lyons(TM) Due 2018:
Elan Corp – 5755
800-252-3526 800-252-3526
ELAN ANNOUNCES COMMENCEMENT OF TENDER PERIOD FOR LYONS(TM) DUE
2018
DUBLIN IRELAND, NOVEMBER 14, 2003-- Elan Corp oration, plc (NYSE: ELN) today
announced that holders of Liquid Yield Option(TM) Notes due 2018 (Zero
Coupon--Subordinated) (the "LYONs") issued by
_____________
dt 271399
|
| Preview
Full Doc
| 2003 |
Elan Announces Commencement of Tender Period for Lyons(TM) Due 2018
Elan Announces Commencement of Tender Period for Lyons(TM) Due 2018 (7K)
Doc #302600: Click preview link for longer preview.
{DOCUMENT}
{TYPE}EX-5.A
{SEQUENCE}8
{FILENAME}elanex5a.txt
{DESCRIPTION}PRESS RELEASE
{TEXT}
Exhibit a(5)(A)
FOR immediate RELEASE
Investors: Media:
Emer Reynolds Anita Kawatra
Ph: 353-1-709-4000 Ph: 212-407-5755
800-252-3526 800-252-3526
ELAN announces commencement of tender period for lyons(TM) due 2018 Dublin,
Ireland, november 14, 2003-- Elan Corporation, plc (NYSE: ELN) today announced
that holders of Liquid Yield Option(TM) Notes due 2018 (Zero
Coupon--Subordinated) (the "LYONs") issued by its wholly-owned subsidiary, Elan
Finance Corporation Ltd., have the right to surrender their LYONs for purchase
during the period that begins today and ends on Monday, December 15, 2003.
Pursuant to the indenture under which the LYONs were issued in December 1998,
each holder of LYONs has the right to require Elan to purchase, until 5:00 p.m.,
New York time, on Monday, December 15, 2003, such holder's LYONs at a price
equal to $616.57 per $1,000 principal amount at maturity of the LYONs.
Under the terms of the LYONs, Elan had the option to pay for the LYONs in cash,
in American Depositary Shares ("ADSs"), representing Ordinary Shares, of Elan,
or in any combination of cash and ADSs. Elan has elected to pay for the LYONs in
cash. The aggregate principal amount due at maturity for all outstanding LYONs
is approximately $801.2 million. If all outstanding LYONs were surrendered for
purchase, the aggregate cash purchase price would be approximately $494 million.
Elan intends to use a portion of the net proceeds from its recently completed
offerings of Ordinary Shares and 6.5% Guaranteed Convertible Notes due 2008 to
repurchase the LYONs.
In order to surrender LYONs for purchase, holders must deliver a purchase notice
to The Bank of New York, the trustee and paying agent for the LYONs, on or
before 5:00 p.m., New York time, on Monday, December 15, 2003. Holders may
withdraw any LYONs previously surrendered for purchase at any time prior to 5:00
p.m., New York time, on Monday, December 15, 2003.
{PAGE}
Elan Announces Commencement of Tender Period for LYONs(TM) due 2018
Page 2
Elan filed a Tender Offer Statement on Form TO with the Securities and Exchange
Commission today. Elan will make available to LYONs holders, through The
Depository Trust Company, documents specifying the terms, conditions and
procedures for surrendering for purchase and withdrawing LYONs. LYONs holders
are encouraged to read these documents carefully before making any decision with
respect to the surrender of LYONs, because these documents contain important
information regarding the details of Elan's obligation to purchase LYONs.
The LYONs are exchangeable into 13.75 Elan ADSs per $1,000 principal amount at
maturity of LYONs, subject to certain conditions set forth in the indenture and
in the LYONs, and subject to adjustment under certain circumstances.
This press release does not constitute an offer to purchase LYONs. The offer to
purchase is made solely by Elan's notice dated November 14, 2003.
About Elan
Elan is focused on the discovery, development, manufacturing, selling and
marketing of novel therapeutic products in neurology, pain management and
autoimmune diseases. Elan shares trade on the New York, London and Irish Stock
Exchanges.
The recent offerings of Ordinary Shares and Guaranteed Convertible Notes were
made outside the United States to non-U.S. persons in reliance on Regulation S
under the Securities Act of 1933, as amended (the "Securities Act"). The
Ordinary Shares, the Guaranteed Convertible Notes, the guarantee of the
Guaranteed Convertible Notes and the shares to be issued upon conversion of the
Guaranteed Convertible Notes have not been and will not be registered under the
Securities Act and, unless so registered, may not be offered, sold or
distributed within the United States or to U.S. persons (as defined in
Regulation S under the Securities Act) except pursuant to an exemption from, or
in a transaction not subject to, the registration requirements of the Securities
Act. This release does not constitute an offer to sell or the solicitation of an
offer to buy any Guaranteed Convertible Notes or Ordinary Shares.
This document contains forward-looking statements about Elan's financial
condition, results of operations and business prospects that involve substantial
risks and uncertainties. You can identify these statements by the fact that they
use words such as "anticipate", "estimate", "project", "envisage", "intend",
"plan", "believe" and other words
{PAGE}
Elan Announces Commencement of Tender Period for LYONs(TM) due 2018
Page 3
and terms of similar meaning in connection with any discussion of future
operating or financial performance or events. Among the factors that could cause
actual results to differ materially from those described herein are the
following: the outcome of Elan's recovery plan and its ability to maintain
flexibility and maintain sufficient cash, liquid resources, and investments and
other assets capable of being monetised to meet its liquidity requirements; the
outcome of the ongoing SEC investigation and the shareholder and other pending
litigation; the success of research and development activities and the speed
with which regulatory authorisations and product launches may be achieved;
competitive developments affecting Elan's current products; the ability to
successfully market both new and existing products; difficulties or delays in
manufacturing; the ability to meet generic and branded competition after the
expiration of Elan's patents; the trend towards managed care and health care
cost containment; possible legislation affecting pharmaceutical pricing;
exposure to product liability and other types of lawsuits; Elan's ability to
protect its intellectual property; interest rate and foreign currency exchange
rate fluctuations; governmental laws and regulations affecting domestic and
foreign operations, including tax obligations; general changes in U.S. and Irish
generally accepted accounting principles; growth in costs and expenses; changes
in product mix; and the impact of acquisitions, divestitures, restructurings,
product withdrawals and other unusual items. A further list and description of
these risks, uncertainties and other matters can be found in Elan's Annual
Report on Form 20-F for the fiscal year ended December 31, 2002, and in its
Reports of Foreign Issuer on Form 6-K. Elan assumes no obligation to update any
forward-looking statements, whether as a result of new information, future
events or otherwise.
{/TEXT}
{/DOCUMENT}
302600
|
BNY
As referenced in this Elan Announces Commencement of Tender Period for Lyons(TM) Due 2018:
Bank of New York, – Convertible Notes due 2008 to
repurchase the LYONs.
In order to surrender LYONs for purchase, holders must deliver a purchase notice
to The Bank of New York, the trustee and paying agent for the LYONs, on or
before 5:00 p.m., New York time, on Monday, December 15,
_____________
dt 267706
;
|
Elan
As referenced in this Elan Announces Commencement of Tender Period for Lyons(TM) Due 2018:
Elan Corp – 5755
800-252-3526 800-252-3526
ELAN announces commencement of tender period for lyons(TM) due 2018 Dublin,
Ireland, november 14, 2003-- Elan Corp oration, plc (NYSE: ELN) today announced
that holders of Liquid Yield Option(TM) Notes due 2018 (Zero
Coupon--Subordinated) (the "LYONs") issued by
_____________
dt 271400
|
| Preview
Full Doc
| 2004 |
Malan Realty Investors Announces Sale of Three Properties; Final Redemption of 9.5% Convertible Subordinated Debentures
Malan Realty Investors Announces Sale of Three Properties; Final Redemption of 9.5% Convertible Subordinated Debentures (5K)
Doc #266853: Click preview link for longer preview.
{DOCUMENT}
{TYPE}EX-99.1
{SEQUENCE}2
{FILENAME}k85114exv99w1.txt
{DESCRIPTION}PRESS RELEASE ISSUED APRIL 29, 2004
{TEXT}
{PAGE}
EXHIBIT 99.1
News Release
FOR FURTHER INFORMATION:
John Roberson Fred Nachman
Media Relations Marjan Communications Inc.
(248) 644-7110 (312) 867-1771
FOR IMMEDIATE RELEASE
MALAN REALTY INVESTORS ANNOUNCES SALE OF THREE PROPERTIES;
FINAL REDEMPTION OF
9.5% CONVERTIBLE SUBORDINATED DEBENTURES
BINGHAM FARMS, MICH., APRIL 29, 2004 - MALAN REALTY INVESTORS, INC.
(NYSE: MAL), a self-administered real estate investment trust (REIT), today
announced it has completed the sale of three properties totaling 392,736 square
feet. Net proceeds from the sales were $8.7 million.
Broadway Center, at 101 W. Lincoln Highway in Merrillville, Indiana is
a 177,692 square-foot property anchored by Kmart. It was sold to Kmart. A
106,084 square-foot Kmart property at 151 E. Riverside Boulevard in Loves Park,
Illinois, was sold to an individual. A Topeka, Kansas property, located at 240
E. 29th Street, houses a Harbor Freight Tools store and consists of 108,960
square feet of space. It was acquired by KDL, Inc.
Malan also announced it is calling the balance of its 9.5% Convertible
Subordinated Debentures due July 15, 2004 for redemption on June 1, 2004. The
Debentures will be redeemed at par, plus accrued but unpaid interest, and
retired. The aggregate principal balance of the Debentures is currently $7.1
million.
"We are pleased to complete the redemption of the convertible
subordinated debentures well in advance of their due date," said Jeffery Lewis,
chief executive officer of Malan Realty Investors. "This is an important
landmark in our strategy to de-leverage the company and create liquidity for the
stockholders. Property sales are also progressing well, and we are pleased with
our progress to date and the prospects for selling additional properties in the
future."
The Debentures currently trade on the New York Stock Exchange under the
CUSIP number 561063-AA-6001. Prior to 5:00 p.m., Eastern Time, on June 1, 2004,
holders of Debentures may convert their Debentures into shares of Malan common
stock at a price of $17.00 per share, or approximately 58.82 shares per $1,000
principal amount of Debentures. Cash will be paid in lieu of fractional shares.
On April 29, 2004, the
{PAGE}
closing price of Malan common stock on the New York St |